MP33-05 NEOADJUVANT PLATINUM-BASED CHEMOTHERAPY FOR CLINICALLY NODE-POSITIVE PENILE SQUAMOUS CELL CARCINOMA: AN INTERNATIONAL, MULTICENTER, REAL-WORLD STUDY

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP33-05 NEOADJUVANT PLATINUM-BASED CHEMOTHERAPY FOR CLINICALLY NODE-POSITIVE PENILE SQUAMOUS CELL CARCINOMA: AN INTERNATIONAL, MULTICENTER, REAL-WORLD STUDY Kyle Rose, Darren Sanchez, Arfa Mustasam, Kathryn Marchetti, Reagan Sandstrom, Lance Pagliaro, Niki Millward, Constantine Alifrangis, Kelvin Moses, Maarten Albersen, Eduard Roussel, Viraj Master, Bahzel Nazha, Tony Zhuang, Jeffrey Montgomery, Chris Protzel, Marcos Tobias-Machado, Philippe Spiess, Curtis Pettaway, and Jad Chahoud Kyle RoseKyle Rose More articles by this author , Darren SanchezDarren Sanchez More articles by this author , Arfa MustasamArfa Mustasam More articles by this author , Kathryn MarchettiKathryn Marchetti More articles by this author , Reagan SandstromReagan Sandstrom More articles by this author , Lance PagliaroLance Pagliaro More articles by this author , Niki MillwardNiki Millward More articles by this author , Constantine AlifrangisConstantine Alifrangis More articles by this author , Kelvin MosesKelvin Moses More articles by this author , Maarten AlbersenMaarten Albersen More articles by this author , Eduard RousselEduard Roussel More articles by this author , Viraj MasterViraj Master More articles by this author , Bahzel NazhaBahzel Nazha More articles by this author , Tony ZhuangTony Zhuang More articles by this author , Jeffrey MontgomeryJeffrey Montgomery More articles by this author , Chris ProtzelChris Protzel More articles by this author , Marcos Tobias-MachadoMarcos Tobias-Machado More articles by this author , Philippe SpiessPhilippe Spiess More articles by this author , Curtis PettawayCurtis Pettaway More articles by this author , and Jad ChahoudJad Chahoud More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003266.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The efficacy of neoadjuvant platinum-based chemotherapy (NAPC) in locally advanced Penile Squamous Cell Carcinoma (PSCC) has been demonstrated in prior small studies, leaving clinicians with scant evidence-based guidance. Thus, we aimed to provide evidence on real-world outcomes of patients with PSCC who received NAPC prior to surgical resection. METHODS: Patients who had undergone NAPC prior to surgical resection for PSCC were included from ten centers. Patients had locally advanced (cTany, cN+), non-metastatic (M0) disease. Clinicopathologic data, chemotherapeutic agents utilized including TIP (Paclitaxel - Ifosfamide - Cisplatin), surgical modalities, and clinicopathologic outcomes were assessed. The primary outcome was overall survival (OS), analyzed using Kaplan-Meier Method and compared using Cox Proportional Hazard Modelling. The secondary outcome was progression-free survival (PFS). Response was determined via best overall response measured with RECIST 1.1 criteria following completion of NAPC. RESULTS: 167 patients with PSCC treated with NAPC were included, 137 (84%) of whom received TIP. 92 (55%) patients died during follow up, and the median follow up for survivors was 57 months. The median OS was 42.0 months, while the median PFS was 17.0 months. After NAC, 22% had progressive disease (PD), 20% had stable disease, 47% had partial response, and 11% had complete response, with median OS of 16 months, 51 months, 56 months, and 119 months, respectively (p<0.01). Predictors for OS and RFS included lymphovascular invasion, positive number of lymph nodes, extranodal extension, downstaging after chemotherapy, best overall response, and ypN status. Figure 1 demonstrates OS outcomes by RECIST best response after chemotherapy, presence of downstaging after NAPC, ypN stage, and presence of extranodal extension. CONCLUSIONS: NAPC is effective in patients with lymph node metastases from PSCC. This study represents the largest conglomeration of multi-institutional penile carcinoma patients treated with upfront cisplatin based therapy, and provides further supportive data for multimodal therapy for advanced penile cancer patients while prospective clinical trials complete accrual . Source of Funding: NA © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e451 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kyle Rose More articles by this author Darren Sanchez More articles by this author Arfa Mustasam More articles by this author Kathryn Marchetti More articles by this author Reagan Sandstrom More articles by this author Lance Pagliaro More articles by this author Niki Millward More articles by this author Constantine Alifrangis More articles by this author Kelvin Moses More articles by this author Maarten Albersen More articles by this author Eduard Roussel More articles by this author Viraj Master More articles by this author Bahzel Nazha More articles by this author Tony Zhuang More articles by this author Jeffrey Montgomery More articles by this author Chris Protzel More articles by this author Marcos Tobias-Machado More articles by this author Philippe Spiess More articles by this author Curtis Pettaway More articles by this author Jad Chahoud More articles by this author Expand All Advertisement PDF downloadLoading ...